The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neuro bromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m 2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are suf cient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% con dence interval estimate of the objective response rate was 0.665 to 0.895. Twentyone patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children. Neuro-Oncology 2, 213-220, 2000 (Posted to Neuro-Oncology [serial online], Doc. 00-022, September 6, 2000 
. For many patients with NF-1, the tumor may be asymptomatic at presentation and may progress slowly over years. In contrast, the incidence of NF-1 among all patients presenting with OPT has been estimated at 25% to 30% in large series (Dutton, 1994; Housepian and Chi, 1993) and may be higher because many reports fail to mention a search for features of the disease.
Controversy continues over the most appropriate treatment of progressive OPTs in children (Dutton, 1994; Hoffman et al., 1993; Hoyt and Baghdassarian, 1969; Jenkin et al., 1993) . Tumors con ned to the optic nerve with severe proptosis and vision loss have been successfully treated with surgery, with 85% to 100% long-term survival (Wright et al., 1980 (Wright et al., , 1989 . However, surgical resection provides limited bene t for children with chiasmal tumors and is associated with the potential morbidity of blindness and hypothalamic damage (Dutton, 1994; Jenkin et al., 1993; Wisoff et al., 1990) . Radiation therapy has been a treatment of choice for progressive OPTs for more than 3 decades. With irradiation doses over 4500 cGy, stabilization of vision and suppression of tumor growth have been reported in 65% to 90% of patients (Flickinger et al., 1988; Horwich and Bloom, 1985; Pierce et al., 1990) . However, there are potential complications associated with CNS irradiation in very young children, including hypothalamic dysfunction, learning disabilities, and cerebrovascular disease (Dutton, 1994) .
Recent reports suggest that chemotherapy may be a useful adjunctive therapy in progressive OPTs. Packer et al. reported a 62.5% progression-free survival among 24 patients (median follow-up of 4.3 years) with progressive OPT under 5 years of age at diagnosis when treated with vincristine and actinomycin-D (Packer et al., 1988) . In a POG phase II study, carboplatin produced stable disease in 9 of 12 patients with recurrent low-grade astrocytic neoplasms for periods up to 68+ months (Friedman et al., 1992) . Transient neutropenia and thrombocytopenia were the principal toxicities observed. Other investigators have also reported responses in low-grade gliomas treated with carboplatin (Charrow et al., 1993; Moghrabi et al., 1993) . Based on these early results, POG-initiated a phase II trial of carboplatin in children less than 6 years of age with progressive OPTs. The objective of the study was to determine the response to treatment. We now report the long-term outcome for these patients.
Patients and Methods

Eligibility
All patients younger than 6 years with symptomatic or progressive OPTs were eligible for treatment. All patients were also enrolled on the natural history protocol (POG 8935) to assess symptom patterns and progression of OPTs in children younger than 21 years. Patients with NF-1 were eligible. Children with hypothalamic masses involving the postchiasmatic pathway were eligible, whereas those without involvement of optic pathway were ineligible. Progressive or symptomatic disease was de ned according to criteria shown in Table 1 .
Before treatment, biopsy was required for any patient with a chiasmatic lesion that extended into the hypothalamus. For all other patients, surgery and biopsy were suggested but not required. All pathologic materials and results of surgery were reviewed centrally. Before study entry, patients were required to have a neurologic assessment, ophthalmologic evaluation, visual evoked response, audiograms, neurodevelopmental tests, and neuro-endocrine evaluation. Neuro-imaging with either CT scan, with and without contrast, or MRI scan, with and without gadolinium, was required. Myelograms and CSF cytology examination were not required. In addition, prechemotherapy studies included a complete blood count, electrolytes, serum calcium and magnesium, creatinine, and alanine aminotransferase.
The protocol was approved by individual institutional review boards, and all patients provided written informed consent.
Treatment Protocol (POG 8936)
Carboplatin was given by i.v. infusion at a dose of 560 mg/m 2 over 1 h. Chemotherapy was given in the outpatient setting every 4 weeks. For patients with stable disease or better, therapy was repeated every 4 weeks for a total of 18 cycles. If platelet count was less than 50,000/ml or absolute neutrophil count was less than 500/ml between treatment cycles, the next course of carboplatin was reduced by 25%. If neutrophil and platelet count nadirs recovered within the next 4-week cycle, attempts were made to escalate the next dose to 100%. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria.
Evaluation of Response
The principal objectives of this study were to assess response to therapy and to monitor the duration of EFS, which is measured from the beginning of treatment. Disease recurrence, disease progression, or death from any cause was regarded as a treatment failure. Neuro-imaging studies and visual acuity were performed before study entry and after two cycles (8 weeks) of chemotherapy. Responses were based primarily on CT or MRI results and were categorized as follows. A complete response was the complete disappearance of the lesion. Partial response and minor response were de ned to be at least a 50% decrease or at least a 25% to less than 50% decrease, respectively, in the product of the maximum perpendicular diameters of the lesion, with no evidence of progression and no new lesions. Stable disease was a less than 25% decrease or increase in the maximum perpendicular diameters of the lesion with no evidence of progression and no new lesions. Anything other than complete response, partial response, minor response, or stable disease was considered progressive disease and included any of the following: a 2-mm increase in the diameter of the optic nerve; an increase in tumor distribution involving the optic tract or optic radiations as indicated by CT or MRI scan using T1 with and without contrast and T2 imaging; contrast enhancement on CT or MRI; progressive visual loss; or increasing papilledema and/or hydrocephalus. Patients with stable disease or better after 2 cycles of carboplatin were continued on study. Neuro-imaging was repeated every 3 months during chemotherapy. Patients completing 18 cycles were than imaged every 2 months for the rst 6 months off therapy and then every 6 months thereafter.
Patients were considered to be off protocol or "off study" for purposes of analysis when there was evidence of progressive disease after one or more courses of chemotherapy or if intolerable toxicity was observed.
Statistical Considerations
The primary objective of this phase II ef cacy study was to determine whether the proportion of objective responses to this carboplatin-based chemotherapy regimen exceeded 0.30, where an objective response was de ned to be one of the the following: complete response, partial response, minor response, or stable disease. Secondary objectives of this study were to provide a 95% con dence interval estimate of the objective response rate and to monitor the type and degree of the toxicities. On May 9, 1992, the original accrual objective of 25 evaluable patients was increased to 40 evaluable patients to help determine whether radiation therapy could be deferred by treatment with carboplatin. In fact, the study closed with 50 eligible and evaluable patients. Included in this report are Kaplan-Meier (Kaplan and Meier, 1958) EFS and survival curves with standard errors (Peto et al., 1977) for all eligible patients and all eligible neuro bromatosis patients (Figs. 1 and 2) , and EFS curves for nonneuro bromatosis patients versus neuro bromatosis patients (Fig. 3) . Because formal survival analy-D.H. Mahoney, Jr., et al.: Carboplatin and optic pathway tumors ses were not study objectives and, therefore, were not preplanned, these curves only provide anecdotal information. No statistical signi cance can be or is presented with them.
Results
Eligible Patients
Between June 1989 and March 1994, 50 patients with progressive OPTs were enrolled and eligible for study. All patients were younger than 6 years. The median age at diagnosis was 1.96 years (range, 4 months to 5.5 years). There were 30 females and 20 males. Neuro bromatosis was present in 21 of 50 patients. Thirty-three patients with signs and symptoms of progressive OPTs were eligible for immediate entry on the treatment protocol (POG 8936), whereas 17 patients were initially registered on the natural history protocol (POG 8935) and not treated with carboplatin until there was evidence of progression by visual changes or neuro-imaging.
Locations of OPTs are shown in Table 2 . Tumors involved the chiasm and/or adjacent structures in 49 of 50 patients. In many patients, at presentation the tumor mass was large, measuring 3 ´3 cm or greater based on two-dimensional maximum perpendicular diameters. Twenty-ve of 50 patients had disease extending into the hypothalamus and 2 of 50 had leptomeningeal disease at diagnosis. Visual loss or other visual symptoms were a typical presenting complaint. Thirty of 50 patients had surgery. A biopsy alone was performed in 16 patients and a partial resection in 14 patients. In 27 patients, a diagnosis of pilocytic astrocytoma was con rmed by central review. Further details on the extent of these ndings and changes after therapy are the subject of a separate report (POG 8935, Natural History Study).
Response to Treatment
Of the 50 eligible and evaluable patients, the overall best responses were 2 with partial response, 37 with stable disease, and 11 with no response or progressive disease after two courses of chemotherapy. Among the cohort of 39 patients with partial response or stable disease, 4 patients progressed before completing 18 months of treatment, and 1 patient with stable disease, who was treated off protocol with alternative therapy, remained progression-free. There were 34 patients who completed 18 months of therapy with partial response or stable disease. Six of these patients developed progressive disease posttherapy. Overall, 6 patients died secondary to tumor progression. These mortalities were observed in 5 nonneuro bromatosis patients with large chiasmatic tumors (4) and/or leptomeningeal dissemination (1). 
Probability
Among the 21 neuro bromatosis patients, 14 patients had stable disease and 1 patient had partial response after two courses of chemotherapy. Overall, 9 neurobromatosis patients went on to develop progressive disease, with one death. Twelve patients continue with stable disease off all chemotherapy.
The 39 objective responses among the 50 eligible and evaluable patients are suf cient to conclude that the proportion of objective responses to this therapy exceeded 0.30 (P < 0.0001), and the approximate 95% con dence interval estimate for the true objective response rate was 0.665 to 0.895.
Kaplan-Meier EFS and survival curves for all eligible patients and for all eligible neuro bromatosis patients are presented in Figs. 1 and 2 . EFS curves for nonneuro bromatosis versus neuro bromatosis patients appear in Fig. 3 . Because no formal survival analyses were planned for this study, no statistical comparisons are presented in conjunction with the curves, which only provide anecdotal information that may be useful in planning other studies.
Toxicity
The signi cant toxicities reported during continuation of therapy with carboplatin are shown in Table 3 . The principal toxicities were transient neutropenia, thrombocytopenia, and mild anemia. Allergic reactions were reported in 3 patients and resulted in discontinuation of therapy in 1 patient.
Discussion
This study represents the largest single series of children with progressive OPTs treated with single-agent chemo- a One or more observations may occur in each patient.
b Number of patients per group.
Probability
therapy. To prevent further progression of disease, 50 eligible children younger than 6 years were treated with a single infusion of carboplatin every 4 weeks for 18 cycles, or until progression of disease. Most of the children had large chiasmatic tumors, and 50% showed extension into the hypothalamus. Stabilization of disease was the common response to therapy. In total, 34 children who began therapy with carboplatin completed 18 months of planned treatment without progression. The EFS curves in Fig. 3 suggest that children with NF-1 fared as well or better than children without NF-1. The primary rationale for using chemotherapy to treat young children who have progressive OPTs has been the desire to delay the need for radiotherapy or other forms of treatment that are potentially damaging. Radiation therapy has been the mainstay of therapy for children with progressive OPTs (Dutton, 1994; Horwich and Bloom, 1985; Jenkin et al., 1993; Kovalic et al., 1990; Pierce et al., 1990) . However, signi cant complications frequently follow the use of such therapy in young children. Atrophy of normal brain parenchyma, growth hormone de ciencies, precocious puberty, diabetes insipidus, and neurodevelopmental disorders have all been associated with irradiation (Brauner et al., 1990; Davis et al., 1986; Duffner and Cohen, 1991; Dutton, 1994; Housepian and Chi, 1993; Okuno et al., 1985) . Radiationinduced cerebral vasculopathy and second malignancy are also risks, especially for children with NF-1 (Grill et al., 1999; Imes and Hoyt, 1986; Sayli et al., 1993) .
There are few published series on the role of chemotherapy for managing progressive OPTs. Packer et al. (1988) rst reported on the ef cacy of vincristine and actinomycin-D in delaying the need for radiation therapy in children younger than 5 years with OPTs. Prados et al. (1997) reported stabilization of chiasmal and hypothalamic gliomas in a mixed group of children between the ages of 4 months and 16 years after treatment with a 5-drug regimen. In this trial, the median time to tumor progression was 132 weeks (a 95% con dence interval was 106-186 weeks). Chamberlain and Grafe (1995) reported responses in 8 of 14 patients with recurrent chiasmatic-hypothalamic gliomas treated with 21-day courses of oral etoposide.
Recently, Packer et al. (1993) reported the results of a carboplatin and vincristine treatment in a series of children aged 3 months to 16 years with low-grade gliomas, including OPTs. Using carboplatin 175 mg/m 2 for 4 consecutive weeks and vincristine 1.5 mg/m 2 for the rst 3 weeks, and repeating each cycle every 7 weeks, the investigators obtained an estimated 3-year progression-free survival of 74% (SE 7%) for children 5 years or younger. It is dif cult to compare outcome of Packer's series with that of our patients because we did not plan any survival analyses, his description of extent of disease at diagnosis was different, and the follow-up was shorter. In our series, 25 patients had evidence of hypothalamic invasion and 11 had hydrocephalus, clinical features associated with poorer prognosis.
Taken together, these clinical trials suggest that progressive OPTs may be successfully treated and stabilized with minimal toxicity for months or years with singleagent or multiagent chemotherapy.
Controversy remains as to what is the optimal treatment for young children with OPTs. We and others suggest that chemotherapy should be considered as the initial therapy in young children with progressive OPTs. The results of this trial with carboplatin suggest that this agent is active against OPTs and that patients failing chemotherapy can be salvaged with alternative treatments, including radiation, in most cases. Clinical trials that seek to add additional agents to a carboplatin backbone must carefully consider the risks for additional toxicity and second malignancy (as might be associated with procarbazine and etoposide) versus the potential for improved EFS. Future randomized clinical trials with single or multiagent chemotherapy may help to further resolve questions of safety and ef cacy in this challenging group of patients.
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